XOMA is engaged in the discovery and development of antibody-based therapeutics. The company's product candidates include: X213, an allosteric inhibitor of prolactin action and humanized IgG1-Kappa monoclonal antibody that binds to the extracellular domain of the human prolactin receptor; and XMetA, which is an insulin receptor-activating antibody designed to provide reduction of hyperglycemia in Type 2 diabetic patients. The company also has two oncology and oncology-related preclinical product candidates: interleukin 2, which for metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor portfolio, which is a G-protein-coupled receptor involved in the regulation of calcium metabolism.
  • TickerXOMA
  • ISINUS98419J2069
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

Jonathan Moreland

InsiderInsights Daily Ratings Report: May 14, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Liana Moussatos ...
  • Shveta Dighe

Q1 Financials; Partner Updates and Dilution

Jonathan Moreland

InsiderInsights Daily Ratings Report: May 14, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Liana Moussatos ...
  • Shveta Dighe

Q1 Financials; Partner Updates and Dilution

A director sold 39,540 shares at 6.245USD and

A director at Xoma Corp sold 39,540 shares at 6.245USD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

ValuEngine Rating and Forecast Report for XOMA

MarketLine Department

Ionis Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Ionis Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ionis Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch